Double-blind comparison of trovafloxacin and doxycycline in the treatment of uncomplicated chlamydial urethritis and cervicitis

Sexually Transmitted Diseases

Volumn 26, Issue 9, 1999, Pages 531-536

  Mccormack, William M ^a   Dalu, Ziad A ^b   Martin, David H ^c   Hook III, Edward W ^d   Laisi, Raija ^e   Kell, Philip ^f   Pluck, Nigel D ^g   Johnson, Raymond B ^h  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

^b Sexually Transmitted Diseases Clinic   (United States)

^c Louisiana Stt Univ Medical School   (United States)

^d University of Alabama at Birmingham   (United States)

^e Aurora Hospital   (Finland)

^f WHITTINGTON HOSPITAL   (United Kingdom)

^g PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^h PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXYCYCLINE; TROVAFLOXACIN;

ADOLESCENT; ADULT; ARTICLE; CHLAMYDIA TRACHOMATIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ERADICATION THERAPY; FEMALE; HEADACHE; HUMAN; MALE; MULTICENTER STUDY; NAUSEA; NEISSERIA GONORRHOEAE; NONHUMAN; ORAL DRUG ADMINISTRATION; TREATMENT OUTCOME; URETHRITIS; UTERINE CERVICITIS; VERTIGO; VOMITING;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; CHLAMYDIA INFECTIONS; CHLAMYDIA TRACHOMATIS; DOUBLE-BLIND METHOD; DOXYCYCLINE; FEMALE; FLUOROQUINOLONES; HUMANS; MALE; MIDDLE AGED; NAPHTHYRIDINES; SEX FACTORS; URETHRITIS; UTERINE CERVICITIS;

EID: 0032847638     PISSN: 01485717     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007435-199910000-00009     Document Type: Article

References (28)

1. Scholes D, Stergachis A, Heidrich FE, et al. Prevention of pelvic inflammatory disease by screening for cervical chlamydial infection. N Engl J Med 1996; 334:1362-1366.
2. Majeroni BA. Chlamydial cervicitis: complications and new treatment options. Am Fam Physician 1994; 49:1825-1829.
3. The World Health Report 1996. World Health Organization. Geneva, Switzerland, 1996: 33.
4. Schmid GP, Fontanarosa PB. Evolving strategies for management of the nongonococcal urethritis syndrome [editorial]. JAMA 1995; 274: 577-579.
5. Washington AE, Katz P. Cost of and payment source for pelvic inflammatory disease: trends and projections, 1983 through 2000. JAMA 1991; 266:2565-2569.
6. Levine WC, Berg AO, Johnson RE, et al. Development of sexually transmitted diseases treatment guidelines, 1993: new methods, recommendations, and research priorities. Sex Transm Dis 1994; 21(suppl 2):S96-S101.
7. Hook EW III, Pinson GB, Blalock CJ, Johnson RB. Dose-ranging study of CP-99,219 (trovafloxacin) for treatment of uncomplicated gonorrhea. Antimicrob Agents Chemother 1996; 40:1720-1721.
8. Knapp JS, Neal SW, Parekh MC, Rice RJ. In vitro activity of a new fluoroquinolone, CP-99,219, against strains of Neisseria gonorrhoeae. Antimicrob Agents Chemother 1995; 39:987-989.
9. Eliopoulos GM, Klimm K, Eliopoulos CT, et al. In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria. Antimicrob Agents Chemother 1993; 37:366-370.
10. Gooding BB, Jones RN. In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridone. Antimicrob Agents Chemother 1993; 37:349-353.
11. Neu HC, Chin N-X. In vitro activity of the new fluoroquinolone CP-99,219. Antimicrob Agents Chemother 1994; 38:2615-2622.
12. Spangler SK, Jacobs MR, Appelbaum PC. Activity of CP 99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin-tazobactam against 489 anaerobes. Antimicrob Agents Chemother 1994; 38:2471-2476.
13. Teng R, Harris SC, Nix DE, et al. Pharmacokinetics and safety of trovafloxacin (CP-99,219), a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers. J Antimicrob Chemother 1995; 36:385-394.
14. Pascual A, Garcia I, Ballesta S, Perea EJ. Uptake and intracellular activity of trovafloxacin in human phagocytes and tissue-cultured epithelial cells. Antimicrob Agents Chemother 1997; 41:274-277.
15. Wise R, Mortiboy D, Child J, Andrews JM. Pharmacokinetics and penetration into inflammatory fluid of trovafloxacin (CP99,219). Antimicrob Agents Chemother 1996; 40:47-49.
16. Martin DH, Jones RB, Johnson RB. A phase II study of trovafloxacin for the treatment of Chlamydia trachomatis infections. Sex Transm Dis 1999; 26(7):369-373.
17. Hook EW III, Jones RB, Martin DH, et al. Comparison of ciprofloxacin and ceftriaxone as single-dose therapy for uncomplicated gonorrhea in women. Antimicrob Agents Chemother 1993; 37:1670-1673.
18. Jones RB, Van Der Pol B, Johnson RB. Susceptibility of Chlamydia trachomatis to trovafloxacin. J Antimicrob Chemother 1997; 39(suppl B):63-65.
19. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically. 3rd ed, approved standard. NCCLS document M7-A3. Villanova, Pa: NCCLS, 1993.
20. Fleiss JL. Statistical Methods for Rates and Proportions. New York, NY: John Wiley & Sons, 1981.
21. Handsfield HH, Ronald AR. Corey L, McCutchan JA. Evaluation of new anti-infective drugs for the treatment of sexually transmitted chlamydial infections and related clinical syndromes. Clin Infect Dis 1992; 15(suppl 1):S131-139.
22. Van Der Pol BJ, Jones RB. Comparison of immunotyping of Chlamydia trachomatis by indirect fluorescent-antibody staining and radioimmunoassay. J Clin Microbiol 1992; 30:1014-1015.
23. Washington AE, Cates W Jr, Wasserheit JN. Preventing pelvic inflammatory disease. JAMA 1991; 266:2574-2580.
24. Hillis S, Black C, Newhall J, et al. New opportunities for chlamydia prevention: applications of science to public health practice. Sex Transm Dis 1995; 22:197-202.
25. Katz BP, Zwickl BW, Caine VA, Jones RB. Compliance with antibiotic therapy for Chlamydia trachomatis and Neisseria gonorrhoeae. Sex Transm Dis 1992; 19:351-354.
26. Childs S, Gleason D, Immergut M, et al. Penetration of trovafloxacin into prostatic tissue following multiple dosing in man In: Abstracts of the 37th Interscience Conference on Antimicrobial agents and Chemotherapy, Toronto, Ontario, Canada: American Society for Microbiology. September 28-October 1, 1997; 14. Abstract A-67.
27. Hendershot EF. Fluoroquinolones. Infect Dis Clin North Am 1995; 9:715-730.
28. Guay DRP. The role of the fluoroquinolones. Pharmacotherapy 1992; 12(6 pt 2):71S-85S.